Cancer

Cover image for Vol. 120 Issue 8

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.201

ISI Journal Citation Reports © Ranking: 2012: 32/197 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 131
  1. Original Articles

    1. Discipline

      Clinical Trials
      Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study

      Emilio Bajetta, Laura Catena, Nicola Fazio, Sara Pusceddu, Pamela Biondani, Giusi Blanco, Sergio Ricci, Michele Aieta, Francesca Pucci, Monica Valente, Nadia Bianco, Chiara Maria Mauri and Francesca Spada

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28726

      This is the first multicenter phase 2 trial on the activity and safety of first-line therapy with everolimus plus octreotide long-acting repeatable (LAR) in advanced neuroendocrine tumors (NETs) with different histotypes. This study demonstrates the potential activity of the combination everolimus-octreotide LAR to achieve a tumor shrinkage in NETs of all primary sites, independently from presence or absence of carcinoid syndrome.

    2. Medical Oncology
      You have full text access to this OnlineOpen article
      A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)

      Gerold Bepler, Ralph G. Zinner, James Moon, Royce Calhoun, Kemp Kernstine, Charles C. Williams, Philip C. Mack, Vasco Oliveira, Zhong Zheng, Philip J. Stella, Mary W. Redman and David R. Gandara

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28714

      Excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are promising predictive markers for the efficacy of platinum agents and gemcitabine. The current phase 2 trial was designed to assess the feasibility and preliminary efficacy of using molecular testing of surgically resected tumor specimens for therapeutic decision-making in a cooperative group environment.

  2. Erratum

    1. You have free access to this content
  3. Original Articles

    1. Discipline

      Psychosocial Oncology
      Early retirement in cancer patients with or without comorbid mental health conditions: A prospective cohort study

      Susanne Singer, Alexandra Meyer, Sabine Wienholz, Susanne Briest, Anna Brown, Andreas Dietz, Harald Binder, Sven Jonas, Kirsten Papsdorf, Jens-Uwe Stolzenburg, Uwe Köhler, Jörg Raßler, Rüdiger Zwerenz, Katharina Schröter, Anja Mehnert, Margrit Löbner, Hans-Helmut König and Steffi G. Riedel-Heller

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28716

      Mental health conditions are risk factors for early retirement in cancer patients. This effect differs according to the type of mental disorder and the patient's income level.

  4. Editorials

    1. Cancer rehabilitation and prehabilitation may reduce disability and early retirement

      Julie K. Silver

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28713

      Prehabilitation and rehabilitation are essential components of high-quality cancer care. Screening followed by evidence-based, interdisciplinary rehabilitation interventions improves physical and psychological health outcomes and will likely reduce work-related disability and the risk of early retirement in survivors.

  5. Review Articles

    1. Magnetic resonance imaging in patients with newly diagnosed breast cancer: A review of the literature

      Melissa Pilewskie and Tari A. King

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28700

      Data do not support the routine use of breast magnetic resonance imaging (MRI) in patients with newly diagnosed breast cancer. MRI is a useful adjunct in specific populations, such as women with occult primary breast cancer, or for assessing response to neoadjuvant chemotherapy.

  6. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: A population-based study of 28,844 patients

      Paul Youn, Michael T. Milano, Louis S. Constine and Lois B. Travis

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28733

      Long-term survivors of adolescent and young adult (aged 15 years-39 years) bone and soft tissue sarcoma experience significantly increased risks of death due to second cancers and noncancer causes. Further research is needed to develop preventive and surveillance guidelines to reduce long-term excess mortality in this understudied population.

    2. Genitourinary Disease
      Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non–muscle-invasive bladder cancer

      Bassel G. Bachir, Alice Dragomir, Armen G. Aprikian, Simon Tanguay, Adrian Fairey, Girish S. Kulkarni, Rodney H. Breau, Peter C. Black and Wassim Kassouf

      Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28731

      The authors performed a cost-effectiveness study comparing sequential therapy with bacillus Calmette-Guerin alone. The results suggest that sequential therapy is a cost-effective treatment for patients with high-risk non–muscle-invasive bladder cancer.

  7. Review Articles

    1. Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer

      Adrian G. Sacher, Pasi A. Jänne and Geoffrey R. Oxnard

      Article first published online: 17 APR 2014 | DOI: 10.1002/cncr.28723

      The widespread adoption of epidermal growth factor receptor (EGFR) kinase inhibitors for the first-line treatment of patients with advanced EGFR-mutated non-small cell lung cancer has resulted in kinase inhibitor resistance becoming a ubiquitous clinical problem. In this article, the authors review the mechanisms, clinical management, and emerging therapies for acquired resistance in patients with EGFR-mutated non-small cell lung cancer.

    2. Surgical management of localized soft tissue tumors

      Alessandro Gronchi, Chiara Colombo and Chandrajit P. Raut

      Article first published online: 17 APR 2014 | DOI: 10.1002/cncr.28715

      The surgical approach to soft tissue tumors has undergone significant changes over the past 10 years. A better understanding of the natural history of the different histologic subtypes, the importance of tumor site, and the different sensitivity to available drugs has opened the way to advances in the individualized treatment of most of them.

  8. Original Articles

    1. Discipline

      Clinical Trials
      Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

      David S. Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina Piha-Paul, Apostolia M. Tsimberidou, YueJin Wen, Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy and Razelle Kurzrock

      Article first published online: 17 APR 2014 | DOI: 10.1002/cncr.28701

      Targeting angiogenesis and disrupting the cross-talk between stroma and cancer cells is a promising strategy for cancer treatment. Vascular endothelial growth factor is critical in orchestrating neoangiogenesis. The current study was conducted to evaluate the safety and biological activity of the dual inhibition of the vascular endothelial growth factor pathway with combined bevacizumab and cediranib.

    2. Disease Site

      Genitourinary Disease
      The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base

      Jeffrey M. Martin, Elizabeth A. Handorf, Alexander Kutikov, Robert G. Uzzo, Justin E. Bekelman, Eric M. Horwitz and Marc C. Smaldone

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28697

      Brachytherapy has been shown to be an efficacious and cost-effective treatment among patients with localized prostate cancer. For patients with localized prostate cancer treated at National Cancer Data Base institutions, there has been a steady decline in brachytherapy use since 2003, which may have significant health policy implications.

    3. Gastrointestinal Disease
      Colorectal cancer screening in high-risk groups is increasing, although current smokers fall behind

      Aminat O. Oluyemi, Amy R. Welch, Lisa J. Yoo, Erik B. Lehman, Thomas J. McGarrity and Cynthia H. Chuang

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28707

      Recently, identified high-risk groups for colorectal cancer include the black, obese, diabetic, and smoking populations. The prevalence of colorectal cancer screening is increasing in all high-risk groups; however, current smokers have lower screening odds, which identifies them as a target group for intensified screening efforts.

  9. Review Articles

    1. State of the science in cervical cancer: Where we are today and where we need to go

      Don S. Dizon, Helen J. Mackay, Gillian M. Thomas, Theresa L. Werner, Elise C. Kohn, Dina Hess, Peter G. Rose and Allan L. Covens

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28722

      Resource-rich countries must partner with resource-poor areas to appropriately prevent and manage cervical cancer. Newer generations of cervical cancer clinical trials are required to optimize the prevention, early detection, diagnosis, and treatment of this disease, incorporating the importance of cost-effectiveness, health policy, and public health in the broadest sense.

  10. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

      Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Karla V. Ballman, Mika Leinonen, Ronald P. DeMatteo and Peter Reichardt

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28669

      The most important factors that predict for gastrointestinal stromal tumor recurrence in a patient population treated with surgery and adjuvant imatinib are tumor mitotic count and site in the gastrointestinal tract. The 2 predictive scores developed effectively stratified the risk.

    2. Gastrointestinal Disease
      BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

      Rona Yaeger, Andrea Cercek, Joanne F. Chou, Brooke E. Sylvester, Nancy E. Kemeny, Jaclyn F. Hechtman, Marc Ladanyi, Neal Rosen, Martin R. Weiser, Marinela Capanu, David B. Solit, Michael I. D'Angelica, Efsevia Vakiani and Leonard B. Saltz

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28729

      In this analysis of what to the authors' knowledge is the largest series of BRAF-mutant metastatic colorectal cancer cases published to date, it was found that BRAF-mutant metastatic colorectal tumors are infrequently associated with PIK3CA co-mutation, commonly spread to the peritoneum, less frequently present with disease limited to the liver, and exhibit a shorter survival duration after complete resection of metastatic disease. The data from the current study suggest that BRAF mutation testing has prognostic value in patients with metastatic colorectal cancer, including those undergoing complete resection for curative intent.

    3. Hematologic Malignancies
      Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

      Yesid Alvarado, Hagop M. Kantarjian, Rajyalakshmi Luthra, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Zeev Estrov, Michael Andreeff and Jorge E. Cortes

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28705

      Secondary FLT3-tyrosine kinase domain mutations can arise after treatment with FLT3 inhibitors in patients with FLT3-internal tandem duplication–mutated acute myeloid leukemia. D835/I836 mutations were observed in at least 20% of patients after treatment, and are associated with resistance and poor prognosis.

    4. Chest and Lung Disease
      The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

      Mingchuan Zhao, Yishi Zhang, Weijing Cai, Jiayu Li, Fei Zhou, Ningning Cheng, Ruixin Ren, Chao Zhao, Xuefei Li, Shengxiang Ren, Caicun Zhou and Fred R. Hirsch

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28725

      In this study, the incidence a of Bim deletion polymorphism is approximately 13%, and it is associated with a poor clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in Chinese patients who have EGFR mutations.

    5. Gastrointestinal Disease
      Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States

      Gery P. Guy Jr, Lisa C. Richardson, Michael P. Pignone and Marcus Plescia

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28724

      A national colorectal cancer screening program would make a substantial public health impact. An organized fecal immunochemical test-based screening program may be an affordable approach to increase screening for colorectal cancer.

    6. Chest and Lung Disease
      Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

      Youngjoo Lee, Geon Kook Lee, Yeon-Su Lee, Wenji Zhang, Jung-Ah Hwang, Byung-Ho Nam, Seok Hyun Kim, Joo-Hang Kim, Tak Yun, Ji-Youn Han, Heung Tae Kim and Jin Soo Lee

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28711

      The presence of a preexisting T790M mutation is not rare event in patients with epidermal growth factor receptor-mutant lung cancer and the frequency of the T790M mutation within a tumor has a critical impact on the tumor's biological characteristics and the clinical outcomes of therapy with epidermal growth factor receptor tyrosine kinase inhibitors.

    7. Melanoma
      Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

      Vincent Launay-Vacher, Sarah Zimner-Rapuch, Nicolas Poulalhon, Thibault Fraisse, Valérie Garrigue, Morgane Gosselin, Sabine Amet, Nicolas Janus and Gilbert Deray

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28709

      Several cases of vemurafenib renal toxicity have been reported in the literature, whereas nephrotoxicity did not appear as a potential side effect of therapy in clinical development of the drug. This is the first case series reporting several cases, with analysis of data available so far, on how such a toxicity may occur.

    8. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD–negative acute myeloid leukemia

      Shuang Qu, Bin Liu, Xiaoling Guo, Hongshun Shi, Meifeng Zhou, Li Li, Shulan Yang, Xiuzhen Tong and Haihe Wang

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28668

      FLT3-ITD–negative acute myeloid leukemia (AML) accounts for up to approximately 70% to 80% of all cases. This study demonstrates that PRL-3, an independent driver in FLT3-ITD–negative AML, is adversely correlated to patient survival. Mechanistically, PRL-3 can promote AML cell cycle progression and render antiapoptosis features to AML cells,suggesting it could be an independent factor for AML diagnosis and therapy.

    9. Gastrointestinal Disease
      BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts

      Aimee L. Lucas, Laura E. Frado, Caroline Hwang, Sheila Kumar, Lauren G. Khanna, Elana J. Levinson, John A. Chabot, Wendy K. Chung and Harold Frucht

      Article first published online: 15 APR 2014 | DOI: 10.1002/cncr.28662

      The results of the current study demonstrate a yield of 18.9% for clinical BRCA1 and BRCA2 germline genetic testing in an unaffected cohort of patients at high risk of developing pancreatic cancer, and 21.8% in an affected cohort of patients with pancreatic cancer, suggesting that both BRCA1 and BRCA2 testing is useful in pancreatic cancer risk stratification and alters risk assignment and screening recommendations for mutation-positive patients and their families. Clinical BRCA1/2 testing should be considered in patients of Ashkenazi Jewish descent with a personal or family history of pancreatic ductal adenocarcinoma, even in the absence of a family history of breast and ovarian cancer.

    10. Genitourinary Disease
      Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study

      Christopher M. Booth, D. Robert Siemens, Gavin Li, Yingwei Peng, Ian F. Tannock, Weidong Kong, David M. Berman and William J. Mackillop

      Article first published online: 14 APR 2014 | DOI: 10.1002/cncr.28510

      Perioperative chemotherapy remains underutilized in routine clinical practice. The results of this large contemporary population-based study suggest that adjuvant chemotherapy is associated with substantial improvement in the general population.

  11. Erratum

    1. You have free access to this content
  12. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use

      Edoardo G. Giannini, Giorgio Sammito, Fabio Farinati, Francesca Ciccarese, Anna Pecorelli, Gian Lodovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Giuseppe Cabibbo, Martina Felder, Antonio Gasbarrini, Rodolfo Sacco, Francesco Giuseppe Foschi, Gabriele Missale, Filomena Morisco, Gianluca Svegliati Baroni, Roberto Virdone, Franco Trevisani and for the Italian Liver Cancer (ITA.LI.CA) Group

      Article first published online: 10 APR 2014 | DOI: 10.1002/cncr.28706

      In patients with hepatocellular carcinoma, serum levels of α-fetoprotein are influenced by sex, characteristics of chronic liver disease, and features of tumor aggressiveness. These findings confirm the limits of using α-fetoprotein as a clinical aid in patients with known or suspected hepatocellular carcinoma.

    2. Discipline

      Disparities Research
      Guideline-concordant cancer care and survival among American Indian/Alaskan Native patients

      Sara H. Javid, Thomas K. Varghese, Arden M. Morris, Michael P. Porter, Hao He, Dedra Buchwald, David R. Flum and for the Collaborative to Improve Native Cancer Outcomes (CINCO)

      Article first published online: 7 APR 2014 | DOI: 10.1002/cncr.28683

      Fewer American Indian/Alaskan Native patients than white patients receive guideline-concordant cancer treatment for the 4 most common cancers (breast, colon, prostate, and lung). Nonreceipt of guideline-concordant treatment is associated with worse survival; however, when such treatment is received, the disease-specific survival of American Indians/Alaskan Natives and whites does not differ significantly.

    3. Disease Site

      Hematologic Malignancies
      Limited utility of routine surveillance imaging for classical hodgkin lymphoma patients in first complete remission

      Sai Ravi Pingali, Sarah W. Jewell, Luiza Havlat, Martin A. Bast, Jonathan R. Thompson, Daniel C. Eastwood, Nancy L. Bartlett, James O. Armitage, Nina D. Wagner-Johnston, Julie M. Vose and Timothy S. Fenske

      Article first published online: 7 APR 2014 | DOI: 10.1002/cncr.28698

      Clinical surveillance is not inferior to routine surveillance imaging for patients with classical Hodgkin lymphoma who achieve complete remission with frontline therapy. Routine surveillance imaging is associated with significantly increased estimated imaging charges.

    4. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines

      Timothy G. Call, Aaron D. Norman, Curtis A. Hanson, Sara J. Achenbach, Neil E. Kay, Clive S. Zent, Wei Ding, James R. Cerhan, Kari G. Rabe, Celine M. Vachon, Emily J. Hallberg, Tait D. Shanafelt and Susan L. Slager

      Article first published online: 7 APR 2014 | DOI: 10.1002/cncr.28690

      The incidence rates per 100,000 population of chronic lymphocytic leukemia (CLL) and high-count monoclonal B-cell lymphocytosis using the International Workshop on Chronic Lymphocytic Leukemia 2008 criteria are 6.8 per 100,000 and 3.5 per 100,000, respectively. The median time to treatment for chronic lymphocytic leukemia classified according those 2008 criteria versus the National Cancer Institute Working Group 1996 criteria is shorter (6.5 years vs 9.2 years).

    5. Gastrointestinal Disease
      Patterns of recurrence after trimodality therapy for esophageal cancer

      Jennifer A. Dorth, John A. Pura, Manisha Palta, Christopher G. Willett, Hope E. Uronis, Thomas A. D'Amico and Brian G. Czito

      Article first published online: 7 APR 2014 | DOI: 10.1002/cncr.28703

      To the authors' knowledge, there is no consensus as to which regional lymph nodes should be targeted with radiation among patients with esophageal cancer and patterns of failure are poorly defined. In the current series, 2-year rates of lymph node failure (NF) and isolated lymph node failure were 14% and 3%, respectively.

    6. Head and Neck Disease
      Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module

      David I. Rosenthal, Tito R. Mendoza, Clifton D. Fuller, Katherine A. Hutcheson, X. Shelley Wang, Ehab Y. Hanna, Charles Lu, Adam S. Garden, William H. Morrison, Charles S. Cleeland and G. Brandon Gunn

      Article first published online: 7 APR 2014 | DOI: 10.1002/cncr.28672

      This prospective, patient-reported, symptom assessment study revealed the pattern and severity of both local and systemic symptoms, symptom clusters, and symptom interference during radiotherapy or concurrent chemoradiotherapy for patients with head and neck cancer. These findings will facilitate the rational development of needed clinical studies for symptom and symptom cluster intervention and prevention.

    7. Hematologic Malignancies
      Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network

      Alex F. Herrera, Allison Crosby-Thompson, Jonathan W. Friedberg, Gregory A. Abel, Myron S. Czuczman, Leo I. Gordon, Mark S. Kaminski, Michael M. Millenson, Auayporn P. Nademanee, Joyce C. Niland, Scott J. Rodig, Maria A. Rodriguez, Andrew D. Zelenetz and Ann S. LaCasce

      Article first published online: 4 APR 2014 | DOI: 10.1002/cncr.28676

      A high discordance rate was observed between referring diagnoses and expert hematopathology review of T-cell lymphomas. In 1 in 10 patients, expert review resulted in a pathologic reclassification that may have impacted treatment.

  13. Editorials

    1. Patient-derived sarcoma xenografts for individual-patient selection of chemotherapy—ready for prime time?

      Andrew J. Wagner

      Article first published online: 4 APR 2014 | DOI: 10.1002/cncr.28694

      Patient-derived sarcoma tumor xenografts can be successfully grown in mice and tested for sensitivity to chemotherapy regimens. Are these tests ready to guide patient care?

  14. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      Patient-derived xenografts for individualized care in advanced sarcoma

      Justin Stebbing, Keren Paz, Gary K. Schwartz, Leonard H. Wexler, Robert Maki, Raphael E. Pollock, Ronnie Morris, Richard Cohen, Arjun Shankar, Glen Blackman, Victoria Harding, David Vasquez, Jonathan Krell, Daniel Ciznadija, Amanda Katz and David Sidransky

      Article first published online: 4 APR 2014 | DOI: 10.1002/cncr.28696

      Each cancer in each individual patient is a separate, heterogynous entity endowed with a unique natural history and a variable number of usually unpredictable, patient-specific, interacting events. The results herein support the use of patient-derived xenografts in sarcoma as a reliable and consistent method to provide direction for optimizing personalized cancer treatment.

    2. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

      Aristoteles Giagounidis, Ghulam J. Mufti, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Kuolung Hu, Paul Woodard, Allen S. Yang and Hagop M. Kantarjian

      Article first published online: 4 APR 2014 | DOI: 10.1002/cncr.28663

      Romiplostim increases platelet counts and decreases bleeding events and platelet transfusions in patients with low-risk/intermediate-1–risk myelodysplastic syndrome. The study drug has been stopped because of concerns regarding increased blast counts and progression to acute myeloid leukemia; survival and acute myeloid leukemia rates are similar, and follow-up is ongoing.

  15. Review Articles

    1. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma

      Geoffrey W. Krampitz and Jeffrey A. Norton

      Article first published online: 3 APR 2014 | DOI: 10.1002/cncr.28661

      MEN2 is a genetic syndrome caused by mutations in the RET proto-oncogene with different penetrance producing 3 variants, MEN2A, MEN2B, and FMTC, each of which is characterized by MTC. The discovery of RET mutations that cause MEN2 lead to the development of genetic testing that enabled personalized approaches to diagnosis, risk stratification, and appropriate treatment.

  16. Erratum

    1. You have free access to this content
  17. Original Articles

    1. Disease Site

      Chest and Lung Disease
      Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study

      Masakuni Serizawa, Yasuhiro Koh, Hirotsugu Kenmotsu, Mitsuhiro Isaka, Haruyasu Murakami, Hiroaki Akamatsu, Keita Mori, Masato Abe, Isamu Hayashi, Tetsuhiko Taira, Tomohiro Maniwa, Toshiaki Takahashi, Masahiro Endo, Takashi Nakajima, Yasuhisa Ohde and Nobuyuki Yamamoto

      Article first published online: 3 APR 2014 | DOI: 10.1002/cncr.28604

      This prospective tumor genotyping study reveals the frequencies of driver mutations and clinicopathologic correlations with each genotype in 411 Japanese lung adenocarcinoma patients. This study also highlights the importance of incorporating multimutational testing in the clinic.

    2. Head and Neck Disease
      The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: Evidence to support a revision of the American Joint Committee on Cancer staging system

      Ardalan Ebrahimi, Ziv Gil, Moran Amit, Tzu-Chen Yen, Chun-Ta Liao, Pankaj Chaturvedi, Jai Prakash Agarwal, Luiz P. Kowalski, Hugo F. Kohler, Matthias Kreppel, Claudio R. Cernea, Jose Brandao, Gideon Bachar, Andrea Bolzoni Villaret, Dan Fliss, Eran Fridman, K. Thomas Robbins, Jatin P. Shah, Snehal G. Patel, Jonathan R. Clark and The International Consortium for Outcome Research (ICOR) in Head and Neck Cancer.

      Article first published online: 1 APR 2014 | DOI: 10.1002/cncr.28686

      This multicenter international study of 3704 patients with oral squamous cell carcinoma demonstrated significant heterogeneity in prognosis based on the number of metastatic lymph nodes (≤ 2, 3-4, and ≥ 5) in patients with both N2b and N2c lymph node disease. Furthermore, the prognoses of patients with N2b and N2c disease were similar after adequate adjustment for the burden of lymph node metastases, irrespective of laterality. Based on these results, the authors propose a modification of the American Joint Committee on Cancer lymph node staging system that is associated with a significant improvement in prognostic accuracy.

    3. Discipline

      Pediatric Oncology
      Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era

      Brian H. Kushner, Shakeel Modak, Kim Kramer, Michael P. LaQuaglia, Karima Yataghene, Ellen M. Basu, Stephen S. Roberts and Nai-Kong V. Cheung

      Article first published online: 1 APR 2014 | DOI: 10.1002/cncr.28687

      While patients with MYCN-nonamplified, high-risk neuroblastoma display a broad, continuous spectrum of response/outcome, patients with MYCN-amplified neuroblastoma either have an excellent response to induction with a good long-term outcome or develop early progressive disease with rapid demise. This striking dichotomy supports investigating the 2 subsets of MYCN-amplified tumors to identify prognostic markers at diagnosis that also may yield insights for targeted therapy.

    4. Radiation Oncology
      Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base

      David J. Sher, Matthew Koshy, Michael J. Liptay and Mary Jo Fidler

      Article first published online: 1 APR 2014 | DOI: 10.1002/cncr.28677

      In this large national database of patients treated for stage III non-small cell lung cancer with definitive chemoradiotherapy, the use of conformal radiotherapy was found to significantly improve overall survival. This finding highlights the importance of radiotherapy delivery and optimal locoregional therapy for the successful treatment of this disease.

    5. Translational Research
      Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas

      Alec E. Vaezi, Gerold Bepler, Nikhil R. Bhagwat, Agnes Malysa, Jennifer M. Rubatt, Wei Chen, Brian L. Hood, Thomas P. Conrads, Lin Wang, Carolyn E. Kemp and Laura J. Niedernhofer

      Article first published online: 1 APR 2014 | DOI: 10.1002/cncr.28643

      The monoclonal antibody 8F1 has been used to determine ERCC1 levels to predict platinum efficacy and as a prognostic marker for the survival of patients with malignancies. The results of the current study demonstrate that 8F1 detects 2 unrelated proteins, ERCC1 and choline phosphate cytidylyltransferase-α (CCTα), and that CCTα is prognostic for survival in patients with lung and head and neck squamous cell carcinomas.

    6. Disparities Research
      The longitudinal impact of patient navigation on equity in colorectal cancer screening in a large primary care network

      Sanja Percac-Lima, Lenny López, Jeffrey M. Ashburner, Alexander R. Green and Steven J. Atlas

      Article first published online: 1 APR 2014 | DOI: 10.1002/cncr.28682

      A patient navigation program for colorectal cancer screening improves equity in cancer care for vulnerable patients over a 5-year period. Colorectal cancer screening rates among Latino and non-English–speaking patients at a practice with patient navigation increase over time and become significantly higher than in practices without patient navigation.

  18. Editorials

    1. The 2014 Surgeon General's report: “The Health Consequences of Smoking–50 Years of Progress”: A paradigm shift in cancer care

      Graham W. Warren, Anthony J. Alberg, Andrew S. Kraft and K. Michael Cummings

      Article first published online: 28 MAR 2014 | DOI: 10.1002/cncr.28695

      To the authors' knowledge, the 2014 Surgeon General's report “The Health Consequences of Smoking–50 Years of Progress” provides the first large evidence review of the effects of smoking on the outcomes of patients with cancer, concluding that smoking causes adverse health outcomes, increases all-cause mortality, and increases cancer-specific mortality. This causal evidence has profound implications on providing high-quality cancer care by emphasizing the need to address tobacco use in all patients with cancer.

  19. Original Articles

    1. Disease Site

      Breast Disease
      Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

      Rashmi K. Murthy, Ankur Varma, Priyankana Mishra, Kenneth R. Hess, Elliana Young, James L. Murray, Kimberly H. Koenig, Stacy L. Moulder, Amal Melhem-Bertrandt, Sharon H. Giordano, Daniel Booser, Vicente Valero, Gabriel N. Hortobagyi and Francisco J. Esteva

      Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28689

      Trastuzumab-naive patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer have superior clinical outcomes to those patients treated with trastuzumab-based therapy. Prior trastuzumab exposure should be considered in the design of clinical trials and sequencing of HER2-targeted therapies.

    2. Hematologic Malignancies
      Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia

      Hiroto Inaba, Aditya H. Gaur, Xueyuan Cao, Patricia M. Flynn, Stanley B. Pounds, Viswatej Avutu, Lindsay N. Marszal, Scott C. Howard, Ching-Hon Pui, Raul C. Ribeiro, Randall T. Hayden and Jeffrey E. Rubnitz

      Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28688

      Outpatient intravenous antibiotic prophylaxis reduces the incidence of clinically or microbiologically documented infection and bacteremia, especially viridans streptococcal bacteremia, in children receiving treatment for acute myeloid leukemia. However, vancomycin-resistant enterococcal bacteremia has been documented in patients receiving antibiotic prophylaxis, and approaches to minimize resistance should be explored.

    3. Discipline

      Clinical Trials
      A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma

      Omid Hamid, Robert Ilaria Jr, Claus Garbe, Pascal Wolter, Michele Maio, Thomas E. Hutson, Ana Arance, Paul Lorigan, Jeeyun Lee, Axel Hauschild, Peter Mohr, Marjo Hahka-Kemppinen, Christopher Kaiser, P. Kellie Turner, Ilaria Conti and Jean-Jacques Grob

      Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28635

      The current phase 3 melanoma trial demonstrated greater hematologic toxicity in the group of patients treated with tasisulam compared with those receiving paclitaxel, which was attributed to low tasisulam clearance in a subset of patients. These results underscore the importance of pharmacokinetic monitoring of compounds with complex dosing, even in late-phase studies.

    4. Epidemiology
      Disparities of cancer incidence in Michigan's American Indians : Spotlight on Breast Cancer

      Emily L. Roen, Glenn E. Copeland, Noel L. Pinagtore, Rafael Meza and Amr S. Soliman

      Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28589

      This study describes cancer trends among American Indians (AIs) in Michigan, USA, focusing on breast cancer, in a linked data set of Indian Health Service (IHS), tribal, and state cancer registry data adjusted for misclassification. This state-specific information will help formulate effective, tailored cancer prevention strategies to this population in Michigan. The data linkages methods used in this study are crucial for generating accurate rates and can be effective in addressing misclassification of the AI population and formulating cancer prevention strategies for AIs nationwide.

    5. Outcomes Research
      Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population-based analysis

      Chan Shen, Ya-Chen Tina Shih, Ying Xu and James C. Yao

      Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28653

      This retrospective study suggests a possible survival benefit for the use of octreotide long-acting repeatable (LAR) in elderly patients with distant-stage neuroendocrine tumors with carcinoid syndrome. It also suggests that octreotide LAR is underused in this population despite recommended guidelines.

    6. Disease Site

      Genitourinary Disease
      Brain metastases associated with germ cell tumors may be treated with chemotherapy alone

      Anna Hardt, Jonathan Krell, Peter D. Wilson, Victoria Harding, Simon Chowdhury, Danish Mazhar, Dan Berney, Justin Stebbing and Jonathan Shamash

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28629

      Current data from a single-institution study of patients with advanced testicular germ cell tumors and brain metastases suggest that GAMEC chemotherapy (14-day cisplatin, high-dose methotrexate, etoposide, and actinomycin-D with filgrastim support) can achieve long-term survival on its own, without the need for additional treatment modalities.

    7. Gastrointestinal Disease
      Identification of a characteristic copy number alteration profile by high-resolution single nucleotide polymorphism arrays associated with metastatic sporadic colorectal cancer

      María González-González, Celia Fontanillo, María M. Abad, María L. Gutiérrez, Ines Mota, Oscar Bengoechea, Ángel Santos-Briz, Oscar Blanco, Emilio Fonseca, Juana Ciudad, Manuel Fuentes, Javier De Las Rivas, José A. Alcazar, Jacinto García, Luís Muñoz-Bellvis, Alberto Orfao and José M. Sayagués

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28681

      The authors use high-resolution single nucleotide polymorphism arrays to identify a characteristic copy number alteration profile at diagnosis that involves losses of chromosomes 1p, 17p, and 18q together with gains of chromosomes 7 and 13 among patients with metastatic versus nonmetastatic primary sporadic colorectal cancer. This copy number profile also is associated with poorer patient outcomes, and the involved chromosomal regions harbor specific genes associated with colorectal cancer and/or the metastatic process.

    8. Genitourinary Disease
      Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors

      Anthony E. Rizzardi, Rachel Isaksson Vogel, Joseph S. Koopmeiners, Colleen L. Forster, Lauren O. Marston, Nikolaus K. Rosener, Natalia Akentieva, Matthew A. Price, Gregory J. Metzger, Christopher A. Warlick, Jonathan C. Henriksen, Eva A. Turley, James B. McCarthy and Stephen C. Schmechel

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28646

      Hyaluronan and hyaluronan-mediated motility receptor (HMMR) are associated with biochemical failure in patients with intermediate-grade prostate cancer, supporting a model whereby increased fragmented hyaluronan in tumors stimulates aggressive behavior through HMMR signaling.

    9. Chest and Lung Disease
      Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer

      Christina D. Williams, Ajeet Gajra, Apar K. Ganti and Michael J. Kelley

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28679

      Despite clinical trials demonstrating improved survival with adjuvant chemotherapy for patients with American Joint Committee on Cancer stages I to III non-small cell lung cancer, it is unclear whether this survival benefit extends to broader populations. In the current study, a majority of patients did not receive adjuvant chemotherapy. Adjuvant chemotherapy was found to be associated with improvement in overall survival.

    10. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States

      Loretta J. Nastoupil, Rajni Sinha, Michelle Byrtek, Xiaolei Zhou, Michael D. Taylor, Jonathan W. Friedberg, Brian K. Link, James R. Cerhan, Keith Dawson and Christopher R. Flowers

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28659

      The authors present what to their knowledge is the largest published series to date of prospectively enrolled patients with previously untreated follicular lymphoma in the modern era examining the effectiveness of rituximab maintenance in clinical practice. With > 5 years of follow-up, it was found that, compared with observation, receipt of rituximab maintenance therapy was associated with significantly longer progression-free survival and time to next treatment in previously untreated patients with follicular lymphoma who achieved at least stable disease after rituximab-based induction therapy.

    11. Discipline

      Epidemiology
      Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer

      Hyunseok Kang, Theresa W. Gillespie, Michael Goodman, Seth A. Brodie, Mina Brandes, Maria Ribeiro, Suresh S. Ramalingam, Dong M. Shin, Fadlo R. Khuri and Johann Christoph Brandes

      Article first published online: 24 MAR 2014 | DOI: 10.1002/cncr.28479

      Because epigenetic changes are early events in smoking-induced carcinogenesis, the authors investigated the incidence of smoking-related cancers in patients with long-term use of the histone deacetylase inhibitor valproic acid. Use of valproic acid was associated with a significant reduction in the risk of head and neck cancer (hazards ratio, 0.66; 95% confidence interval, 0.48-0.92).

    12. Quality of Life
      Quality of life changes during the pre- to postdiagnosis period and treatment-related recovery time in older women with breast cancer

      Angela M. Stover, Deborah K. Mayer, Hyman Muss, Stephanie B. Wheeler, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28649

      Women aged 65 years and older who are diagnosed with breast cancer should be counseled that survivors within 6 months of diagnosis are vulnerable to health-related quality of life (HRQOL) declines, compared to older women without breast cancer, but decrements generally wane after 12 months. Similar HRQOL declines occurred across groups receiving breast-conserving surgery, breast-conserving surgery plus radiation, and mastectomy, suggesting that older women choosing any one of these treatment modalities fare equally well for HRQOL.

  20. Review Articles

    1. Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone

      Leona A. Doyle

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28657

      Since the publication of the prior World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone 11 years ago, new clinicopathologic and genetic features of many soft tissue and bone tumors have been characterized, allowing obsolete diagnostic categories to be removed and new tumor types to be added. This article reviews the changes in the 2013 WHO classification, along with new genetic data that have emerged even since the publication of the current volume.

  21. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program

      Chi Young Ok, Zijun Y. Xu-Monette, Alexandar Tzankov, Dennis P. O'Malley, Santiago Montes-Moreno, Carlo Visco, Michael B. Møller, Karen Dybkær, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, J. Han van Krieken, Maurilio Ponzoni, John P. Farnen, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros and Ken H. Young

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28664

      Compared with patients who have cyclin D1-negative diffuse large B-cell lymphoma (DLBCL), men are more commonly affected with cyclin D1-positive DLBCL and are significantly younger. There are no other significant differences in clinical presentation, pathologic features, overall survival, or progression-free survival between these 2 subgroups of patients with DLBCL; however, recognition of such subtypes is critical in the differential diagnosis of lymphoma.

    2. Discipline

      Outcomes Research
      Shared decision-making and patient control in radiation oncology: Implications for patient satisfaction

      Jacob E. Shabason, Jun J. Mao, Eitan S. Frankel and Neha Vapiwala

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28665

      The results of the current study emphasize the importance of shared decision-making and patient-perceived control in management decisions within the field of radiation oncology, particularly as it relates to patient satisfaction and symptoms of psychological distress. Regardless of a patient's desire to be involved in the decision-making process, it is vital for the radiation oncology team to actively engage all patients in the clinical decision-making process.

  22. Editorial

    1. Local treatment of high risk prostate cancer: Role of surgery and radiation therapy

      Tudor Borza and Adam S. Kibel

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28645

      The current management of patients with high-risk prostate cancer is hampered by overstaging. This editorial reviews the referenced article as well as outlines the treatment strategies for patients with aggressive disease.

  23. Original Articles

    1. Disease Site

      Genitourinary Disease
      The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer

      Michael R. Abern, Martha K. Terris, William J. Aronson, Christopher J. Kane, Christopher L. Amling, Matthew R. Cooperberg and Stephen J. Freedland

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28647

      A significant number of men with clinically high-risk prostate cancer have favorable radical prostatectomy pathology. These patients have excellent long-term oncologic outcomes and many will not require adjuvant or salvage therapy.

  24. Editorials

    1. Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources

      Christopher R. Cogle

      Article first published online: 18 MAR 2014 | DOI: 10.1002/cncr.28638

      There is a high number of uncaptured cases with myelodysplastic syndromes (MDS) by population-based cancer registries. A novel method of capture-recapture was used to identify uncaptured MDS cases.

  25. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study

      Zoe K. McQuilten, Erica M. Wood, Mark N. Polizzotto, Lynda J. Campbell, Meaghan Wall, David J. Curtis, Helen Farrugia, John J. McNeil and Vijaya Sundararajan

      Article first published online: 18 MAR 2014 | DOI: 10.1002/cncr.28641

      Previous reports have suggested that myelodysplastic syndromes (MDS) are underreported to cancer registries, and therefore may have a substantially higher incidence. However, whether these findings are broadly applicable is unknown. Using 2 data sources from a different population, a higher incidence of MDS was found than was reported using cancer registry notifications alone as well as differences between reported and nonreported cases.

  26. Commentaries

    1. The Patient Protection and Affordable Care Act: Is it good or bad for oncology?

      Hagop M. Kantarjian, David P. Steensma and Donald W. Light

      Article first published online: 18 MAR 2014 | DOI: 10.1002/cncr.28673

      The Patient Protection and Affordable Care Act (ACA) has many flaws that need to be addressed, but it is better than what was. Oncologists should advocate for the ACA and work on improving it.

  27. Original Articles

    1. Disease Site

      Head and Neck Disease
      Treatment and survival in 10,429 patients with localized laryngeal cancer: A population-based analysis

      Stephanie Misono, Schelomo Marmor, Bevan Yueh and Beth A. Virnig

      Article first published online: 17 MAR 2014 | DOI: 10.1002/cncr.28608

      Single-modality treatment for localized laryngeal cancer has become more common over time, in accordance with standard treatment guidelines. Unexpectedly, better survival was observed for patients whose treatment included local surgery than for those who receive radiation only.

    2. Breast Disease
      Expression of androgen receptor in inflammatory breast cancer and its clinical relevance

      Yun Gong, Wei Wei, Yun Wu, Naoto T. Ueno and Lei Huo

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28667

      Androgen receptor is commonly expressed in inflammatory breast cancer. Patients who have inflammatory breast cancer with androgen receptor-negative/estrogen receptor-negative tumors have significantly worse clinical outcomes than patients who have tumors that exhibit other combinations of androgen receptor/estrogen receptor status.

  28. Original Article

    1. Disease Site

      Gastrointestinal Disease
      Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab

      Shubham Pant, Ludmila K. Martin, Susan Geyer, Lai Wei, Katherine Van Loon, Nilli Sommovilla, Mark Zalupski, Renuka Iyer, David Fogelman, Andrew H. Ko and Tanios Bekaii-Saab

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28648

      Patients with advanced pancreatic cancer with normal baseline serum albumin levels appear to derive benefit from bevacizumab. Future prospective investigations of bevacizumab in the treatment of advanced pancreatic cancer should consider selecting patients with normal baseline serum albumin to maximize potential benefit.

  29. Original Articles

    1. Discipline

      Quality of Life
      Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

      David Cella, Mellar P. Davis, Sylvie Négrier, Robert A. Figlin, M. Dror Michaelson, Andrew G. Bushmakin, Joseph C. Cappelleri, Rickard Sandin, Beata Korytowsky, Claudie Charbonneau, Ewa Matczak and Robert J. Motzer

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28660

      Using phase 3 trial data for sunitinib versus interferon-α in treatment-naive patients with metastatic renal cell carcinoma, retrospective analyses characterized sunitinib-associated fatigue and its impact on patient-reported health-related quality of life. Patients reported worse fatigue during the first sunitinib cycle, but in subsequent consecutive cycles less fatigue was reported with no statistically significant worsening; provider-assessed fatigue did not appear to fully capture patient treatment experience.

    2. Disease Site

      Genitourinary Disease
      Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma

      Sima Porten, Arlene O. Siefker-Radtke, Lianchun Xiao, Vitaly Margulis, Ashish M. Kamat, Christopher G. Wood, Eric Jonasch, Colin P. N. Dinney and Surena F. Matin

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28655

      Neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma compared with a matched historic cohort of patients treated with initial surgery.

  30. Correspondence

    1. Cancer survivorship: Is there a role for cancer survivor clinics?

      Ernesto Zanet, Mariagrazia Michieli and Umberto Tirelli

      Article first published online: 11 MAR 2014 | DOI: 10.1002/cncr.28658

  31. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study

      Alexis D. Leal, Rui Qin, Pamela J. Atherton, Paul Haluska, Robert J. Behrens, Charles H. Tiber, Patanit Watanaboonyakhet, Matthias Weiss, Paul T. Adams, Travis J. Dockter, Charles L. Loprinzi and for the Alliance for Clinical Trials in Oncology

      Article first published online: 11 MAR 2014 | DOI: 10.1002/cncr.28654

      Glutathione is not effective in preventing paclitaxel/carboplatin-induced peripheral neuropathy. In addition, it does not appear to interfere with the antitumor activity of paclitaxel/carboplatin.

  32. Commentaries

    1. Silent diffuse low-grade glioma: Toward screening and preventive treatment?

      Emmanuel Mandonnet, Philip de Witt Hamer, Johan Pallud, Luc Bauchet, Ian Whittle and Hugues Duffau

      Article first published online: 11 MAR 2014 | DOI: 10.1002/cncr.28610

      We show that people with a silent gliomas have more chances to die from their gliomas than from another unrelated cause. This result, combined with the knowledge that diffuse low-grade gliomas remain clinically silent for very long period (>10 years), grounds the screening and preventive treatment of silent diffuse low-grade glioma.

  33. Erratum

    1. You have free access to this content
      Erratum: Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers

      Article first published online: 6 MAR 2014 | DOI: 10.1002/cncr.28666

      This article corrects:

      Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers

      Vol. 120, Issue 7, 1068–1075, Article first published online: 30 DEC 2013

  34. Original Articles

    1. Disease Site

      Genitourinary Disease
      The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease

      Florence K. Keane, Ming-Hui Chen, Danjie Zhang, Marian J. Loffredo, Philip W. Kantoff, Andrew A. Renshaw and Anthony V. D'Amico

      Article first published online: 6 MAR 2014 | DOI: 10.1002/cncr.28609

      The lack of prostate cancer (PC) deaths among men with favorable intermediate-risk PC suggests that adding androgen-suppression therapy may not reduce their risk of PC-specific mortality; whereas many men with unfavorable intermediate-risk PC are at increased risk for harboring occult PC with Gleason scores from 8 to 10 and may benefit from long-term androgen-suppression therapy. Multiparametric magnetic resonance imaging and targeted biopsy of suspicious lesions should be considered to identify occult PC with Gleason scores from 8 to 10 in these men.

    2. Discipline

      Radiation Oncology
      Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy

      Bassem I. Zaki, Arief A. Suriawinata, Alan R. Eastman, Kristen M. Garner and Samuel F. Bakhoum

      Article first published online: 6 MAR 2014 | DOI: 10.1002/cncr.28656

      The role of chromosomal instability (CIN) in tumor response to therapy is poorly understood and has generally been associated with poor prognosis. In the current study, the authors demonstrate that CIN is surprisingly correlated to a favorable response in patients with rectal cancer treated with chemoradiation therapy.

    3. Disparities Research
      Improving colorectal cancer screening in Asian Americans: Results of a randomized intervention study

      Patricia A. Carney, Frances Lee-Lin, Solange Mongoue-Tchokote, Motomi Mori, Holden Leung, Christine Lau, T. Domi Le and David A. Lieberman

      Article first published online: 4 MAR 2014 | DOI: 10.1002/cncr.28640

      An intervention has the greatest influence on a Chinese subgroup, which has improved scores relative to a control group for perceived behavior control and intentions, for behavioral beliefs on cancer screening, and for attitudes toward behavior. An educational program delivered by culturally specific community health educators using culturally appropriate language influences some knowledge, attitude, and behavioral beliefs but not others.

    4. Disease Site

      Gynecologic Oncology
      Clinical outcomes of carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix in phase 1/2 clinical trial (protocol 9704)

      Masaru Wakatsuki, Shingo Kato, Tatsuya Ohno, Kumiko Karasawa, Hiroki Kiyohara, Tomoaki Tamaki, Ken Ando, Hirohiko Tsujii, Takashi Nakano, Tadashi Kamada, Makio Shozu and The Working Group of the Gynecological Tumor

      Article first published online: 3 MAR 2014 | DOI: 10.1002/cncr.28621

      This is the first clinical trial and dose escalation study of carbon ion radiotherapy for adenocarcinoma of the uterine cervix. Dose escalation of carbon ion radiotherapy for adenocarcinoma of the uterine cervix was accomplished safely, with no severe toxicities.

    5. Discipline

      Outcomes Research
      Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era

      Pardha Devaki, Robert J. Wong, Vidyasagargoud Marupakula, Sharad Nangia, Long Nguyen, Ivo C. Ditah, Murray N. Ehrinpreis and Mindie H. Nguyen

      Article first published online: 3 MAR 2014 | DOI: 10.1002/cncr.28639

      Despite meeting the criteria for liver transplantation, nearly one-half of eligible patients with localized hepatocellular carcinoma did not receive any therapy. Even in this current era, racial disparities in long-term survival exist, with black patients found to have the worst survival.

  35. Review Articles

    1. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer

      Mack Roach III

      Article first published online: 3 MAR 2014 | DOI: 10.1002/cncr.28594

      This review examines the clinical evidence underpinning the use of androgen deprivation therapy and radiotherapy for patients with high-risk localized and locally advanced prostate cancer in the United States. It also considers the rationale for moving from traditional luteinizing hormone-releasing hormone agonists to more recently developed gonadotrophin-releasing hormone antagonists.

  36. Editorial

    1. Can we change the past for colorectal cancer patients and how do we move forward?

      Justin Y. Jeon and Jeffrey A. Meyerhardt

      Article first published online: 3 MAR 2014 | DOI: 10.1002/cncr.28567

      Many lifestyle factors, such as diet, physical activity, smoking, alcohol consumption, and adiposity, are modifiable, and there is great interest whether changing these factors could have potential preventive benefits in those without colorectal cancer and adjuvant benefits for those with the disease. A recent study demonstrates that individual exposures and healthier composite lifestyle are associated with improved overall and/or cardiovascular mortality, which highlights to clinicians that colorectal cancer survivors are at risk for other comorbidities that are associated with increased mortality.

  37. Original Articles

    1. Discipline

      Epidemiology
      Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study

      Colleen Pelser, Hannah Arem, Ruth M. Pfeiffer, Joanne W. Elena, Catherine M. Alfano, Albert R. Hollenbeck and Yikyung Park

      Article first published online: 3 MAR 2014 | DOI: 10.1002/cncr.28573

      Several modifiable lifestyle factors measured prediagnosis were related to survival among patients with colorectal cancer. A combined lifestyle score consisting of meeting recommendations for diet, body weight, physical activity, alcohol intake, and smoking was also associated with reduced all-cause mortality.

  38. Editorials

    1. Increasing complexity of high-grade B-cell lymphomas

      James O. Armitage and R. Gregory Bociek

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28637

      Morphologic heterogeneity is only part of the picture for patients with high-grade B-cell lymphomas, and many of these lymphomas are biologically driven by equally complex variations in genetics and protein expression. In this patient population, novel targeted therapies need to be tested in combination with chemoimmunotherapy in the front-line setting, because the proportion of patients who progress early is so high, and many patients do not appear to be salvageable with further conventional chemotherapy regimens.

  39. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

      Jonathon B. Cohen, Susan M. Geyer, Gerard Lozanski, Weiqiang Zhao, Nyla A. Heerema, Nathan C. Hall, Veena A. Nagar, Jessica A. Hemminger, Jeffrey A. Jones, Pierluigi Porcu, Beth A. Christian, Robert A. Baiocchi, Kami J. Maddocks, Joseph M. Flynn, Steven M. Devine and Kristie A. Blum

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28642

      Patients with Myc-positive or double-hit non-Hodgkin lymphoma have inferior progression-free and overall survival. The authors identify a subset of patients who achieve a complete response to induction therapy who have prolonged remission durations.

    2. Discipline

      Symptom Control and Palliative Care
      Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

      David P. Steensma, Rami S. Komrokji, Richard M. Stone, Alan F. List, Guillermo Garcia-Manero, John M. Huber, Betsy Dennison and Mikkael A. Sekeres

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28631

      Patients, physicians, and nonphysician health care professionals have differing perspectives on myelodysplastic syndromes (MDS) and MDS therapy, with physicians viewing the treatment experience less favorably than patients but having a more favorable view of the potential benefits of therapy than patients. Patients with MDS often do not consider MDS a “cancer,” although MDS is classified as such by the World Health Organization, and most patients and nonphysician health care professionals are unaware that MDS can be cured through stem cell transplantation.

  40. Editorials

    1. Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

      Sumanta K. Pal and Robert A. Figlin

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28636

      The current editorial focuses on a phase 2 study evaluating ramucirumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior sunitinib and/or sorafenib therapy. The potential for further development is discussed in the context of the rapidly changing landscape of therapy for mRCC.

  41. Original Articles

    1. Disease Site

      Genitourinary Disease
      A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

      Jorge A. Garcia, Gary R. Hudes, Toni K. Choueiri, Walter M. Stadler, Laura S. Wood, Jayne Gurtler, Shailender Bhatia, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Jonathan D. Schwartz and John A. Thompson

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28634

      In this single-arm, phase 2 trial, ramucirumab monotherapy had a limited impact on the Response Evaluation Criteria in Solid Tumors-defined response of patients with metastatic renal cell carcinoma who either had progression on or developed drug intolerance to vascular endothelial growth factor receptor inhibitory tyrosine kinase inhibitors. However, the median and 1-year progression-free survival rates were encouraging, and ramucirumab was safe and well tolerated.

  42. Editorials

    1. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

      Paolo A. Ascierto and Kim Margolin

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28622

      The use of sequential therapy with ipilimumab and vemurafenib reported by Ackerman et al in this issue demonstrates that patients who failed BRAF inhibitor therapy appeared to have an inferior outcome than patients who received ipilimumab followed by BRAF inhibitor therapy. These results are in line with previous experience and provide additional evidence to support the use of ipilimumab before a BRAF inhibitor in the majority of patients with advanced melanoma who have an activating BRAF mutation and who are treated outside of a clinical trial.

  43. Original Articles

    1. Disease Site

      Melanoma
      Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

      Allison Ackerman, Oliver Klein, David F. McDermott, Wei Wang, Nageatte Ibrahim, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, F. Stephen Hodi, Richard Kefford, Alexander M. Menzies, Michael B. Atkins, Georgina V. Long and Ryan J. Sullivan

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28620

      Four new therapies have been approved by the US Food and Drug Administration from 2011 to 2013 for the treatment of metastatic melanoma, yet there are little data to guide sequencing of these therapies. In a retrospective analysis, immunotherapy does not alter treatment effect of the BRAF inhibitor vemurafenib and treatment with an immunotherapeutic, ipilimumab, is not effective following prior therapy with vemurafenib in patients with BRAF-mutant, metastatic melanoma.

    2. Discipline

      Outcomes Research
      Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials

      Rafael Meza, Kevin ten Haaf, Chung Yin Kong, Ayca Erdogan, William C. Black, Martin C. Tammemagi, Sung Eun Choi, Jihyoun Jeon, Summer S. Han, Vidit Munshi, Joost van Rosmalen, Paul Pinsky, Pamela M. McMahon, Harry J. de Koning, Eric J. Feuer, William D. Hazelton and Sylvia K. Plevritis

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28623

      Five lung cancer natural history models demonstrated that the National Lung Screening Trial and Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial have produced consistent results. The resulting models can be important tools to assess the effectiveness of lung cancer screening strategies using low-dose computed tomography.

  44. Review Articles

    1. What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?

      Damien Urban, June Corry and Danny Rischin

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28595

      This review of oropharyngeal squamous cell carcinoma in the human papillomavirus (HPV) era focuses on current and investigational treatment strategies in patients with HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.

  45. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer

      Rony Dev, David Hui, Egidio Del Fabbro, Marvin O. Delgado-Guay, Nikhil Sobti, Shalini Dalal and Eduardo Bruera

      Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28619

      A high frequency of hypogonadism has been reported in male patients with advanced cancer. In the current study, an increased symptom burden, systemic inflammation, weight loss, opioid use, and poor survival were found to be associated with decreased testosterone levels in male patients with cancer.

  46. Review Articles

    1. You have full text access to this OnlineOpen article
      MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

      Rajesh V. Lalla, Joanne Bowen, Andrei Barasch, Linda Elting, Joel Epstein, Dorothy M. Keefe, Deborah B. McGuire, Cesar Migliorati, Ourania Nicolatou-Galitis, Douglas E. Peterson, Judith E. Raber-Durlacher, Stephen T. Sonis, Sharon Elad and The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO).

      Article first published online: 25 FEB 2014 | DOI: 10.1002/cncr.28592

      Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. This article presents evidence-based clinical practice guidelines for the management of mucositis.

  47. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Prognostic significance of cytoskeleton-associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma

      Shuang-xi Li, Gu-sheng Tang, Dong-xun Zhou, Yu-fei Pan, Ye-xiong Tan, Jian Zhang, Bo Zhang, Zhi-wen Ding, Li-juan Liu, Tian-yi Jiang, He-ping Hu, Li-wei Dong and Hong-yang Wang

      Article first published online: 22 FEB 2014 | DOI: 10.1002/cncr.28593

      The expression of cytoskeleton-associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 are correlated with progression and metastasis in patients with hepatocellular carcinoma and may provide prognostic and therapeutic value.

  48. Erratum

    1. You have free access to this content
  49. Original Article

    1. Discipline

      Symptom Control and Palliative Care
      Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients

      David Hui, Sun Hyun Kim, Joyce Roquemore, Rony Dev, Gary Chisholm and Edurado Bruera

      Article first published online: 22 FEB 2014 | DOI: 10.1002/cncr.28628

      In this retrospective cohort study, patients with advanced cancer who have early access to outpatient palliative care receive less aggressive care at the end of life compared with those who have delayed access to palliative care and those who receive inpatient palliative care. These findings support the need to increase the availability of palliative care clinics and to streamline the process of early referral.

  50. Erratum

    1. You have free access to this content
  51. Original Articles

    1. Disease Site

      Head and Neck Disease
      Causes of death in long-term survivors of head and neck cancer

      Shrujal S. Baxi, Laura C. Pinheiro, Sujata M. Patil, David G. Pfister, Kevin C. Oeffinger and Elena B. Elkin

      Article first published online: 22 FEB 2014 | DOI: 10.1002/cncr.28588

      The cause and timing of death in a large cohort of long-term survivors of head and neck squamous cell carcinoma was evaluated. Through use of a competing risk model, varying risk of death was identified based on demographic and clinical factors including age, primary site of disease, and race.

  52. Editorial

    1. Facing head and neck cancer deaths head on: Lessons for survival

      Jolie Ringash

      Article first published online: 22 FEB 2014 | DOI: 10.1002/cncr.28585

      Despite making up only 3% of all cancers, squamous cell carcinomas of the head and neck (HNC) exemplify complex survivorship care. Characteristics of this cohort of patients include high levels of comorbidity, high baseline risk of psychosocial distress, and exposure to highly toxic treatment strategies. With survival rates of the primary cancer increasing over time, the population at risk for secondary complications (including recurrence, secondary primaries, illnesses induced by risk factors, and injuries related to treatment) is increasing. Recognition of elevated death rates of survivors, persisting up to 10 years after diagnosis, outline the importance of a dedicated approach to HNC survivorship care, whether provided within or outside the comprehensive cancer center.

  53. Original Articles

    1. Discipline

      Disparities Research
      Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period

      Ayal A. Aizer, Tyler J. Wilhite, Ming-Hui Chen, Powell L. Graham, Toni K. Choueiri, Karen E. Hoffman, Neil E. Martin, Quoc-Dien Trinh, Jim C. Hu and Paul L. Nguyen

      Article first published online: 22 FEB 2014 | DOI: 10.1002/cncr.28617

      African American patients with cancer are at an increased risk of cancer-specific mortality compared with white patients. The survival gap for African Americans has not narrowed with time, and in the case of patients with breast cancer, appears to be widening.

  54. Correspondence

    1. How can patients who are not referred for treatment receive the best treatment available?

      Graham W. Warren, James R. Marshall, K. Michael Cummings, Anurag K. Singh and Mary E. Reid

      Article first published online: 20 FEB 2014 | DOI: 10.1002/cncr.28590

VIEW

  1. 1 - 100
  2. 101 - 131

SEARCH

SEARCH BY CITATION